Supreme Court hears arguments on Biden’s vaccine mandate for big business
Jan 07, 2022
The court also was hearing arguments on separate vaccine mandate for most heathcare workers.
mRNA COVID-19 vaccine effectiveness lower during delta strain era
Aug 20, 2021
Adjusted effectiveness was 53.1% against infection in nursing home residents during the period when delta strain was predominant.
Plant-based recombinant COVID-19 vaccine found to be effective
May 04, 2022
Vaccine efficacy ranged from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease.
Single dose of AZD7442 effectively prevents COVID-19
Apr 22, 2022
A relative risk reduction of 82.8% was seen in symptomatic COVID-19 at extended follow-up of a median of six months.
White House considering stronger measures to boost COVID-19 vaccinations
Aug 06, 2021
One option being considered is restricting Medicare dollars or other federal funds from nursing homes and other long-term-care facilities that do not require staff to be vaccinated.
mRNA COVID-19 vaccines immunogenic in immunosuppressed patients
Sep 08, 2021
mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines appear to be immunogenic in patients receiving immunosuppressive medications for the management of chronic inflammatory...
mRNA-1273 continues to be efficacious at five months
Sep 27, 2021
The efficacy of mRNA-1273, the Moderna vaccine, was 93.2% for preventing COVID-19 illness and 98.2% for preventing severe COVID-19.
Protection against omicron strongest with hybrid immunity
Jun 17, 2022
Immunity resulting from previous COVID-19 infection and recent booster vaccination confers the strongest protection against the omicron infection.
Overall risk of myopericarditis low after COVID-19 vaccine
Apr 12, 2022
The overall incidence of myopericarditis does not differ significantly for those receiving COVID-19 vaccines versus non-COVID-19 vaccines.
Homologous, heterologous COVID-19 boosters are immunogenic
Feb 07, 2022
Antibody neutralizing titers against SARS-CoV-2 D614G pseudovirus increased by a factor of 4 to 73 for all combinations.